摘要
目的比较多廿烷醇和瑞舒伐他汀治疗老年高脂血症的有效性、安全性并进行成本-效果分析(Cost-effec-tiveness analysis,CEA)。方法选择我院2009～2010年诊治的60例老年高脂血症,随机分为多廿烷醇组(每日10 mg)及瑞舒伐他汀组(每日5 mg),每组30例,分别治疗6周后观察各组降脂效果并作CEA。结果多廿烷醇组治疗有效率为90%,瑞舒伐他汀组有效率为96.67%,两组比较差异无统计学意义(P=0.69)。均未见严重不良反应。CEA显示多廿烷醇成本-效果比(C/E)为1240,瑞舒伐他汀C/E为193。结论多廿烷醇及瑞舒伐他汀均为安全有效的降脂药物,但瑞舒伐他汀有更高的经济性。
Objective To evaluate the cost-effectiveness analysis（CEA）,efficacy and safety of Policosano and Rosuvastatin in the treatment of senior patients with hyperlipoidemia.Methods 60 senior patients with hyperlipidemia admitted into our hospital during 2011 and 2010 were randomly divided into Policosano group（n=30,10 mg per day）and Rosuvastatin group（n=30,5 mg per day）.6 weeks after treatment,the efficacy was observed,and CEA was performed.Results The Policosanol was similar to Rosuvastatin in decreasing lipidemia.The effective rates in Policosano group and Rosuvastatin group were 90% and 96.67% respectively,and the differences were significant（P=0.69）.There were no adverse reactions in the two groups.CEA showed that C/E of Policosano was 1240,and 193 of Rosuvastatin.Conclusion Policosano and Rosuvastatin are effective and safe in lowering lipidemia,but Rosuvastatin has a higher economic value.
出处
《临床误诊误治》
2011年第10期87-89,共3页
Clinical Misdiagnosis & Mistherapy
